Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II) Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Immunotherapy, Adoptive
  • Ovarian Neoplasms

abstract

  • Although the uncontrolled design of this study prevents definitive conclusions with respect to subgroups, the data support a relationship between Ab3 response and survival time. Thus, the need for further randomized, controlled clinical trials to establish efficacy of the vaccine ACA125 seems to be indicated.

publication date

  • March 2004

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-03-0056

PubMed ID

  • 15014007

Additional Document Info

start page

  • 1580

end page

  • 7

volume

  • 10

number

  • 5